<--- Back to Details
First PageDocument Content
Health / Hepatitis C / Harm reduction / Viral hepatitis / Drug policy of Portugal / Needle-exchange programme / Drug culture / Ethics / Medicine
Date: 2014-12-06 09:29:50
Health
Hepatitis C
Harm reduction
Viral hepatitis
Drug policy of Portugal
Needle-exchange programme
Drug culture
Ethics
Medicine

Add to Reading List

Source URL: www.correlation-net.org

Download Document from Source Website

File Size: 1,13 MB

Share Document on Facebook

Similar Documents

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

DocID: 1vngt - View Document

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes   

DocID: 1vjI2 - View Document

Contact PD/PI: Braithwaite, Ronald Scott A. SPECIFIC AIMS Many persons with HIV have Hepatitis C (HCV) co-infection and consume alcohol.1,2 Now that highly effective and easily tolerated therapies for HCV are available,

DocID: 1vbzY - View Document

PRESS RELEASE AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection  TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C

DocID: 1vais - View Document